Rathbones Group PLC Cuts Stock Holdings in DexCom, Inc. $DXCM

Rathbones Group PLC lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 46.6% in the 1st quarter, Holdings Channel.com reports. The fund owned 63,994 shares of the medical device company’s stock after selling 55,897 shares during the quarter. Rathbones Group PLC’s holdings in DexCom were worth $4,019,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Reflection Asset Management bought a new position in DexCom in the 4th quarter valued at approximately $25,000. Ascentis Independent Advisors bought a new stake in shares of DexCom in the 1st quarter worth $25,000. MCF Advisors LLC bought a new stake in shares of DexCom in the 4th quarter worth $32,000. Wellington Grp LLC raised its stake in shares of DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares during the last quarter. Finally, DV Equities LLC bought a new position in shares of DexCom during the fourth quarter valued at $36,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Argus raised its price target to $96 from $86 and maintained a “buy” rating, implying approximately 10% potential upside from the referenced price. Benzinga
• Positive Sentiment: DexCom’s latest quarterly results exceeded expectations, with adjusted earnings of $0.70 per share versus a $0.61 consensus estimate and revenue of $1.31 billion versus $1.29 billion expected. Revenue increased 13.1% year over year, while operating income reportedly grew 49.7%; management also raised its fiscal-year 2026 guidance. DexCom: Still A Cautious Buy Following Earnings
• Positive Sentiment: Growth catalysts include adoption of the G7 glucose-monitoring system, international expansion and the “Road to 100” initiative aimed at broadening diabetes coverage. Margin improvement, share repurchases and a solid balance sheet further support the investment case. DexCom: Still A Cautious Buy Following Earnings
• Positive Sentiment: Technical momentum has improved: DXCM moved above its 20-day moving average and reached a new 52-week high, signaling continued short-term buying interest. DexCom 52-Week High
• Neutral Sentiment: Analyst opinion remains broadly constructive, with another reported price-target increase to $82; however, targets vary significantly. At roughly 34 times earnings, valuation leaves the stock sensitive to any slowdown in growth or weaker guidance. DexCom Price Target Raised
• Negative Sentiment: Director Mark G. Foletta sold a combined 4,000 shares for approximately $330,640 under a pre-arranged Rule 10b5-1 plan. Because the sales were scheduled in advance and he retains a substantial position, the transactions are a limited negative signal rather than clear evidence of declining confidence. SEC Insider Trading Filing

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. William Blair raised DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Robert W. Baird set a $105.00 target price on DexCom in a research report on Friday. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Argus raised their price target on shares of DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of DexCom in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $88.71.

Insider Buying and Selling

In other DexCom news, insider Kevin R. Sayer sold 26,759 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the sale, the insider owned 382,482 shares of the company’s stock, valued at approximately $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. The trade was a 1.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 102,506 shares of company stock valued at $7,535,898 in the last 90 days. 0.28% of the stock is owned by company insiders.

DexCom Stock Down 0.4%

Shares of DXCM stock opened at $86.94 on Wednesday. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $87.85. The stock has a market cap of $32.81 billion, a P/E ratio of 34.36, a P/E/G ratio of 1.48 and a beta of 1.41. The company has a 50 day simple moving average of $73.74 and a two-hundred day simple moving average of $69.43.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same quarter last year, the company posted $0.48 EPS. The company’s revenue was up 13.1% compared to the same quarter last year. On average, research analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.